OncoMatch/Clinical Trials/NCT04889716
CAR-T Followed by Bispecific Antibodies
Is NCT04889716 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including mosunetuzumab and glofitamab for large b-cell lymphoma.
Treatment: mosunetuzumab · glofitamab · obinutuzumab — The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: anthracycline
at least one prior standard systemic treatment regimen that contains an anthracycline
Must have received: anti-CD20-directed therapy
at least one containing an anti-CD20-directed therapy
Cannot have received: solid organ transplantation
Prior solid organ transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Nebraska Medical Center · Omaha, Nebraska
- Abramson Cancer Center of the University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify